RESVERLOGIX CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.055 CAD | 0.00% |
|
-8.33% | -21.43% |
| Apr. 01 | Resverlogix Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 21 | Resverlogix Corp. Announces Resignation of Shawn Lu from the Board of Directors | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -21.43% | 11M | |
| -1.71% | 103B | |
| +2.49% | 96.73B | |
| +0.09% | 21.31B | |
| -16.61% | 21.21B | |
| -6.13% | 18.79B | |
| -42.14% | 16.37B | |
| -27.40% | 13.68B | |
| +1.44% | 13.44B | |
| +21.29% | 10.98B |
- Stock Market
- Equities
- RVX Stock
- News Resverlogix Corp.
- Resverlogix : Says Apabetalone Demonstrates Medical First in Patients with Chronic Kidney Disease; Research Published in Peer-Reviewed Journal
